| Document |
Document Title |
|
WO/2024/152408A1 |
Disclosed are an alkylzinc reagent, and a preparation method therefor and a use thereof, relating to the technical field of synthetic organic chemistry. The structural general formula of the alkylzinc reagent is R-ZnOPiv·Mg(OPiv)Br, whe...
|
|
WO/2024/153105A1 |
Disclosed in the present invention are a five-membered heterocyclic compound and a pharmaceutical composition thereof and the use thereof. The structure of the five-membered heterocyclic compound is as shown in formula (I). A stereoisome...
|
|
WO/2024/153070A1 |
Provided are certain GLP-1R agonists of formula (I), pharmaceutical compositions thereof, and methods of use thereof.
|
|
WO/2024/081714A3 |
Disclosed herein are new inhibitors of GroEL/ES and HSP60/10 chaperonin systems that serve as new antibiotic candidates against a variety of infectious organisms. The identified compounds can selectively kill Escherichia coli, the ESKAPE...
|
|
WO/2024/149314A1 |
The present invention relates to an aminothiophene compound and a preparation method therefor and a use thereof. The structure of the compound is as shown in formula (I). The shown compound is a novel anti-HBV compound. The present inven...
|
|
WO/2024/151672A1 |
Analogues of dynemicin, methods of their preparation, and their use for treating cancer are disclosed.
|
|
WO/2024/150245A1 |
The present invention relates to a process for preparation of compound of formula (I) that includes the steps of a) hydrogenation of compound of formula (VI) using metal catalyst; b) N-protection of compound of formula (V) with phthalic ...
|
|
WO/2024/151666A1 |
The present disclosure provides a compound of Formula (I) or a pharmaceutically acceptable salt thereof and its use in, e.g. treating a condition, disease, or disorder in which inhibiting GPX4 in a subject is of therapeutic benefit, spec...
|
|
WO/2024/146619A1 |
The present invention relates to an aurone derivative or analog as represented by formula (I), and a preparation method therefor, a pharmaceutical composition thereof and the use thereof. The aurone derivative or analog can be used as an...
|
|
WO/2024/147287A1 |
The present invention provides: an active light sensitive or radiation sensitive resin composition with which a pattern having excellent resolution can be formed; a resist film; a pattern forming method; and a method for producing an ele...
|
|
WO/2024/147149A1 |
The present invention discloses a process for preparing high purity 3-chlorothiophene. The said process comprises the steps of: (a) contacting an impure mixture comprising 3-chlorothiophene with a metal catalyst in the presence of hydrog...
|
|
WO/2024/141543A1 |
The invention concerns a compound of formula (I): the process for the preparation thereof and the use thereof as photoinitiator, preferably as photoinitiator activable under 350-460 nm light irradiation, notably to cure formulations comp...
|
|
WO/2024/142976A1 |
This composition contains a compound represented by formula (1) and a curable compound. In formula (1), PM+ is a cation represented by formula (PM1), and A- is an anion represented by formula (AN1). The present invention pertains to a fi...
|
|
WO/2024/143131A1 |
The purpose of the present invention is to provide: an actinic ray-sensitive or radiation-sensitive resin composition which has excellent LWR performance and enables the reduction of residues after development; a resist film, a pattern f...
|
|
WO/2024/142966A1 |
The problem addressed is: to provide a polymer mechanoradical initiator obtained by mechanochemical treatment of an organic polymer material as a radical initiator for reactions in which the polymer mechanoradical initiator component is ...
|
|
WO/2024/130411A1 |
Inhibitors of the SARS-CoV-2 Mpro protease and methods of their use in treating a coronavirus infection in a subject are provided. The inhibitors may have the general structure (I) :
|
|
WO/2024/131772A1 |
The present application relates to a compound having a STING inhibitory effect and a pharmaceutical composition thereof, and use thereof in the preparation of a medicament for preventing and/or treating diseases related to abnormal STING...
|
|
WO/2024/128017A1 |
Provided is a new sulfonium salt that, when being irradiated with light beams having an ultrashort wavelength, quickly degrades and generates an acid. This sulfonium salt is represented by formula (1). In formula (1), R1 represents an ...
|
|
WO/2024/127977A1 |
The present invention uses a resist composition containing: a base material component of which the solubility in a developer solution changes due to the action of an acid; and a compound represented by general formula (d0). In the formul...
|
|
WO/2024/126674A1 |
The present invention relates to a process for the preparation of relugolix or a pharmaceutically salt thereof. It also relates to new intermediates and their use for the preparation of relugolix.
|
|
WO/2024/122345A1 |
The present invention addresses the problem of providing a method for producing a homo-coupling reaction product, whereby it becomes possible to substantially eliminate the use of an organic solvent, to carry out a reaction under a mild ...
|
|
WO/2024/122301A1 |
The present invention provides a photoelectric conversion element that demonstrates excellent quantum efficiency when receiving blue light. The present invention also provides an imaging device, a photosensor, and a compound that relate ...
|
|
WO/2024/124043A1 |
Compounds of Formula (I) are derivatives of salvinorin A. Such compounds, as well as pharmaceutically acceptable salts and compositions thereof, are useful for treating diseases or conditions a disease or disorder that can be treated wit...
|
|
WO/2024/120149A1 |
The present invention relates to the technical field of liquid crystal materials, and in particular to a dibenzothiophene liquid crystal compound, and a preparation method therefor and a use thereof. The present invention provides a dibe...
|
|
WO/2024/120471A1 |
The present invention provides compounds of formula (I) which can bind to mutant p53 and restore the ability of the p53 mutant to bind DNA and activate downstream effectors involved in tumor suppression. Also provided are pharmaceutical ...
|
|
WO/2024/116207A1 |
Provided herein are compounds identified as inhibitors of ADAR1 activity, such as compounds having the formula: (I) or (II), or a pharmaceutically acceptable salt or tautomer thereof, that are useful in treating cancer and other disorder...
|
|
WO/2024/119131A1 |
A spiro-thiophene compound includes a centroid core having a plurality of benzene rings, and a plurality of thiophene molecules covalently bonded to a carbon atom of the plurality of benzene rings of the centroid core to form a centroid-...
|
|
WO/2024/117003A1 |
Provided is a compound represented by formula (1).
|
|
WO/2024/116780A1 |
The present invention provides: a resist composition that is improved in terms of a decrease in roughness and sensitivity, and that can suppress film reduction during development; a resist pattern formation method that uses the resist co...
|
|
WO/2024/117761A1 |
The present specification relates to a compound of formula 1 and an organic light-emitting element comprising same.
|
|
WO/2024/117265A1 |
The present invention relates to binaphthyl compounds of the formula {I) that are suitable as monomers for preparing thermoplastic resins, such as polycarbonate resins, which have beneficial optical and mechanical properties and can be u...
|
|
WO/2024/114085A1 |
The present invention provides a triarylamine organic functional compound and a use thereof. The compound has a structure as represented by formula (I). The (A) group has a dibenzo five-membered ring or six-membered ring structure. The p...
|
|
WO/2024/110680A1 |
The present invention relates to thiophene derivatives and to the use of these compounds of formula (I) to prevent and/or treat viral diseases. More particularly, the invention relates to the use of these compounds to treat and/or preven...
|
|
WO/2024/108179A2 |
Pharmaceutically active 2-ethylamine substituted benzofuran and benzothiophene compositions are provided for the treatment of mental disorders or for mental enhancement, including for entactogenic therapy. The present invention also incl...
|
|
WO/2024/101044A1 |
Provided are a resist composition in which the temporal stability during storage is increased and a decrease in fine resolution after storage is reduced, a resist pattern formation method using said resist composition, and a compound use...
|
|
WO/2024/099518A1 |
The invention relates to salts and complexes with 3-acetal-4-hydroxybicyclo[3.3.1]non-3-ene-2,9-dione derivatives. According to the invention, the derivatives comprise a compound of the general formula (IA) or (IB), wherein A represents ...
|
|
WO/2024/097831A1 |
Provided herein are, inter alia, unnatural amino acids, proteins comprising unnatural amino acids, biomolecule conjugates, and methods of making the unnatural amino acids, proteins, and biomolecule conjugates. In embodiments, the unnatur...
|
|
WO/2024/095734A1 |
This fluorine-containing heterocyclic compound production method is for obtaining a compound represented by formula (2) through intramolecular cyclization of a compound represented by formula (1). X1 represents a hydrogen atom, a fluorin...
|
|
WO/2024/089216A1 |
Compounds of formula (I) wherein the substituents are as defined in claim 1, and the agrochemically acceptable salts, stereoisomers, enantiomers, tautomers and N-oxides of those compounds, can be used as insecticides.
|
|
WO/2024/090485A1 |
The present invention provides a method for producing a fluorine-containing compound under relatively mild conditions by introducing a fluorine atom into a wide variety of oxygen-containing compounds having a ketone group, an aldehyde gr...
|
|
WO/2024/085386A1 |
It has been identified that an alkynyl amino acid ester derivative preparation method using a photocatalytic reaction, according to the present invention, is simple and enables a linear, cyclic or chiral alkynyl amino acid ester derivati...
|
|
WO/2024/085607A1 |
The present invention provides a novel compound and an organic light-emitting device using same.
|
|
WO/2024/085208A1 |
This compound is a compound represented by formula (1). [In the formula, n represents an integer from 1-3. L1 represents a possibly branched, (n + 1)-valent linking group (but excluding chain saturated aliphatic hydrocarbon groups). ...
|
|
WO/2024/085354A1 |
The present invention provides, in the present specification, a heterocyclic compound and an organic light-emitting device including same.
|
|
WO/2024/084186A1 |
The presentation invention relates to compounds of formula (I) and pharmaceutical compositions thereof. The compounds may be used to treat an infection, such as a parasitic infection or a bacterial infection. In some embodiments, the com...
|
|
WO/2024/079734A1 |
The invention relates to a method for preparing 4-alkoxy carbonyl-3 -aminothiophene of formula (I) or acid- addition salt thereof of formula (I)', which comprises reacting the corresponding 3 -oxotetrahydrothiophenes compound of formula ...
|
|
WO/2024/080128A1 |
The present invention addresses the problem of providing an actinic ray-sensitive or radiation-sensitive resin composition from which a resist pattern having a small LWR can be formed. An actinic ray-sensitive or radiation-sensitive resi...
|
|
WO/2024/078137A1 |
An organic electroluminescent device and an electronic apparatus. The organic electroluminescent device comprises a cathode, an anode, and an organic layer, the organic layer comprises an organic light-emitting layer, and the organic lig...
|
|
WO/2024/081714A2 |
Disclosed herein are new inhibitors of GroEL/ES and HSP60/10 chaperonin systems that serve as new antibiotic candidates against a variety of infectious organisms. The identified compounds can selectively kill Escherichia coli, the ESKAPE...
|
|
WO/2024/076117A1 |
The present invention is an organic compound used in an organic layer provided in an organic light-emitting element. In particular, when the organic compound is used in an electron blocking layer of an organic light-emitting element, it ...
|
